Amplia Therapeutics Limited (ATX)

Overview

Amplia Therapeutics Limited, headquartered in Melbourne, Australia, operates within the pharmaceutical industry, primarily focusing on the development of innovative treatments for cancer and fibrosis. The company specializes in the discovery and development of focal adhesion kinase (FAK) inhibitors, a novel approach in targeting diseases. Established in the year 2000 and initially known as Innate Immunotherapeutics Limited, the company underwent a rebranding to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics is actively engaged in research collaborations, including a notable partnership with the Garvan Institute of Media Research in Sydney, aiming to advance its understanding and development of pharmaceuticals.

Products and Services

• AMP945

An inhibitor of FAK, AMP945 is at the forefront of Amplia Therapeutics' product pipeline. This potential therapeutic is targeted for the treatment of pancreatic cancer and idiopathic pulmonary fibrosis, along with other solid tumors and fibrotic diseases. AMP945 has successfully completed Phase I clinical trials, showcasing the company’s progress in developing effective treatments for these challenging conditions.

• AMP886

Another significant component of Amplia’s portfolio, AMP886, is a promising drug candidate tailored for the treatment of acute myeloid leukemia (AML) and certain solid tumors. Reflecting the company’s strategic aim to expand its therapeutic offerings, AMP886 represents a potential breakthrough in the treatment of difficult-to-treat cancers, emphasizing Amplia's commitment to addressing unmet medical needs.